Cargando…
Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)
[Image: see text] N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048319/ https://www.ncbi.nlm.nih.gov/pubmed/24641010 http://dx.doi.org/10.1021/jm500066b |
_version_ | 1782480522642980864 |
---|---|
author | Rackham, Mark D. Brannigan, James A. Rangachari, Kaveri Meister, Stephan Wilkinson, Anthony J. Holder, Anthony A. Leatherbarrow, Robin J. Tate, Edward W. |
author_facet | Rackham, Mark D. Brannigan, James A. Rangachari, Kaveri Meister, Stephan Wilkinson, Anthony J. Holder, Anthony A. Leatherbarrow, Robin J. Tate, Edward W. |
author_sort | Rackham, Mark D. |
collection | PubMed |
description | [Image: see text] N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high affinity inhibitor of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a previously described series. Development, guided by targeting a ligand efficiency dependent lipophilicity (LELP) score of less than 10, yielded a 100-fold increase in enzyme affinity and a 100-fold drop in lipophilicity with the addition of only two heavy atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for further optimization. |
format | Online Article Text |
id | pubmed-4048319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-40483192014-06-09 Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) Rackham, Mark D. Brannigan, James A. Rangachari, Kaveri Meister, Stephan Wilkinson, Anthony J. Holder, Anthony A. Leatherbarrow, Robin J. Tate, Edward W. J Med Chem [Image: see text] N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high affinity inhibitor of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a previously described series. Development, guided by targeting a ligand efficiency dependent lipophilicity (LELP) score of less than 10, yielded a 100-fold increase in enzyme affinity and a 100-fold drop in lipophilicity with the addition of only two heavy atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for further optimization. American Chemical Society 2014-03-05 2014-03-27 /pmc/articles/PMC4048319/ /pubmed/24641010 http://dx.doi.org/10.1021/jm500066b Text en Copyright © 2014 American Chemical Society Terms of Use CC-BY (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) |
spellingShingle | Rackham, Mark D. Brannigan, James A. Rangachari, Kaveri Meister, Stephan Wilkinson, Anthony J. Holder, Anthony A. Leatherbarrow, Robin J. Tate, Edward W. Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) |
title | Design and Synthesis of High
Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) |
title_full | Design and Synthesis of High
Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) |
title_fullStr | Design and Synthesis of High
Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) |
title_full_unstemmed | Design and Synthesis of High
Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) |
title_short | Design and Synthesis of High
Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) |
title_sort | design and synthesis of high
affinity inhibitors of plasmodium falciparum and plasmodium vivax n-myristoyltransferases directed by ligand efficiency dependent lipophilicity (lelp) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048319/ https://www.ncbi.nlm.nih.gov/pubmed/24641010 http://dx.doi.org/10.1021/jm500066b |
work_keys_str_mv | AT rackhammarkd designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT branniganjamesa designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT rangacharikaveri designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT meisterstephan designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT wilkinsonanthonyj designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT holderanthonya designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT leatherbarrowrobinj designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp AT tateedwardw designandsynthesisofhighaffinityinhibitorsofplasmodiumfalciparumandplasmodiumvivaxnmyristoyltransferasesdirectedbyligandefficiencydependentlipophilicitylelp |